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Background:  Hypoxia is invariably associated with wound repair, inflammation, and vascular disease. 
The induction of Hypoxia Inducible Factor-1 (HIF-1) is a characteristic feature of hypoxia, and 
orchestrates the profound changes in transcription that accompany hypoxia. HIF-1 expression is 
localized to several cell types, and regulates several genes that are important to vascular function 
including vascular endothelial growth factor (VEGF), nitric oxide synthase (NOS), endothelin-1 and 
erythropoietin (EPO). In fact, EPO derived from vascular endothelial cells appears to be important in 
protecting the endothelium against ischemic injury. The non-erythropietic analogue of EPO; 
pyroglutamate helix B surface peptide (pHBSP) retains the protective actions of EPO without its 
erythropoietic effects. The aim of our study was to assess the reparative effects of these molecules when 
used in combination with HIF inducers. 
Method: The reparative effects of EPO and pHBSP were assessed under hypoxia (1% O2) and normoxia 
(21% O2) as well as in the presence or absence of DMOG; a HIF-1 inducer. An in vitro model of wound 
healing (the scratch assay) was used: a monolayer of rat aortic endothelial cells (RAECs) was scraped 
to produce a reproducible injury, and the scratch closure was assessed over 24 h. An in vivo model of 
vascular injury using a 2F fogarty balloon catheter was introduced into the common carotid artery 
causing complete removal of the vascular endothelium. Drugs were applied locally onto the injured 
arteries using a hydrogel (30% w/v) and re-endothelialisation assessed using Evans blue staining 
injected 30 min intravenously before culling the rat. The effects of EPO and pHBSP on cell 
proliferation, chemotaxis and apoptosis were assessed in both the in vitro and in vivo models. The 
potential molecular mechanisms of these effects were also explored. 
Results: In vitro, EPO and its analogues only exhibited a reparative effect under hypoxic conditions (13 
± 2.6 %, and 10 ± 1.69 %, p< 0.01 improvement in the degree of endothelial cell closure after treatment 
with EPO and pHBSP respectively) compared to normoxic conditions (3.2 ± 0.9%, p>0.05). These 
effects appeared to be mediated by promoting RAEC proliferation and migration of (p<0.05). The 
priming effect of hypoxia was associated with stabilization of HIF-1α. Hypoxia was associated with a 
reduction in nitric oxide (NO) production as assessed by its oxidation products nitrite and nitrate, and 
this was consistent with the oxygen requirement for the endogenous production of NO by NO synthase 
(NOS).The HIF-1 inducer; DMOG also exhibited reparative effects in a concentration dependent 
manner.  Similar results were observed in vivo where DMOG and EPO accelerated the repair of injured 
arteries (35 ± 9.8 % recovery compared to untreated injured arteries respectively). This mode of 
application also caused site-specific increase in VEGF expression on treated arteries compared to 
untreated ones within the same animal. 
Conclusion and implication: The tissue-protective effects of EPO-related cytokines in 
pathophysiological settings are enhanced by hypoxia. These findings may be particularly relevant to 
atherogenesis and post-angioplasty restenosis 
 
